% | $
Quotes you view appear here for quick access.

Biodel Inc. (BIOD) Message Board

  • larrystone13 larrystone13 Aug 15, 2013 10:22 AM Flag

    Article : BIOD Price To Go Significantly Higher. LINKED

    Seeking Alpha
    Aug 15 2013, 08:30 | By: Scott Matusow
    This week we list four biopharmaceutical companies that have upcoming catalysts. We expect these company's stock prices to appreciate significantly in the short term as they draw closer their respective catalysts. Smaller cap biotechs have been on a tear lately, with 50 to 100% gains occurring at a substantial rate. Our BioPharma Catalyst Watch List Seeking Alpha
    Seeking Alpha
    Aug 15 2013, 08:30 | By: Scott Matusow
    Biodel (BIOD) is a biopharmaceutical company that focuses on the development and specialization of treatments for diabetes. Biodel's leading drug candidate is BIOD-123, which is an ultra-rapid acting insulin formulation. Biodel has recently been gaining a lot of attention because it has a market cap of under $100M, while the global diabetes market is worth over $10B.

    Biodel is expecting to release results from a Phase II trial in the third quarter of 2013. Biodel CEO Dr. Errol De Souza stated in the second quarter 2013 financial results presentation:

    We are pleased to report progress across the breadth of our portfolio of pipeline product candidates. Enrollment is fully complete in our Phase 2 clinical trial of RHI-based ultra-rapid-acting insulin BIOD-123 and more than half of the subjects have finished the study, as we remain on track to report top line data in the third calendar quarter of 2013.
    Biodel has already produced positive results before for an ultra-rapid acting insulin with its former drug Linjeta. Since the company has decided to create a more advanced formulation (BIOD-123) and has worked
    with the FDA in designing the trials, we expect that there is a strong chance that the company produces positive results

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.2613-0.0528(-16.81%)Jun 24 4:00 PMEDT